+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Clinical-grade Medical Software - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • PDF Icon

    Report

  • 140 Pages
  • July 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6265644
The clinical-grade medical software market size was valued at USD 3.56 billion in 2025 and is estimated to grow from USD 4.24 billion in 2026 to reach USD 10.20 billion by 2031, at a CAGR of 19.18% during the forecast period (2026-2031). This report is Segmented by Clinical Function (Diagnostic, Monitoring, Therapeutic, CDS, Others), Deployment (Cloud-Based, On-Premise, Hybrid), Component (Software, Services), Therapeutics Area (Oncology, Cardiology, Neurology, Radiology, Others), End User (Hospitals, Ascs, Diagnostic Centers, Others), Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Clinical-grade Medical Software Market Trends and Insights

AI-Enabled Clinical Workflow Automation Widens Clinical Productivity Gaps

AI workflow tools are gaining visibility in clinical software purchasing decisions. Ambient documentation tools can reduce manual documentation workloads and give clinicians more time for patient care. Health systems are testing these systems to support tasks that previously depended on manual documentation and coordination. Agent-based systems may shift software value beyond the electronic health record (EHR) toward clinical task coordination, creating opportunities for specialized workflow providers and increasing pressure on established EHR suppliers. Research in a simulated setting found that agentic EHR systems approached experienced physician performance in selected diagnostic tasks, supporting continued clinical evaluation.

EHR, PACS and LIS Integration Demand Redefines Platform Value

Health systems increasingly seek software that works across EHR, PACS, LIS, and analytics systems. Fragmented imaging and laboratory systems, uneven HL7 FHIR adoption, and disconnected IoT data remain barriers to enterprise AI use. The clinical-grade medical software market benefits when vendors connect information without requiring clinicians to leave the patient record. In-context access to images within an active EHR record is becoming a practical requirement for enterprise buyers, while reliable interoperability allows suppliers to compete on operational fit rather than a single feature.

Cybersecurity Exposure Creates a Performance Risk for Clinical Software

Cybersecurity has become a clinical continuity issue, not just an IT concern. Healthcare ransomware incidents rose 58% year over year in 2025. The April 2026 ChipSoft attack showed how a vendor incident can disrupt EHR access across several institutions. Providers now prioritize security, privacy, recovery capabilities, and resilient infrastructure when evaluating clinical software, which can affect confidence in the clinical-grade medical software market, increase vendor engineering costs, and lengthen procurement cycles.

Other drivers and restraints analyzed in the detailed report include:

  • Regulatory and Reimbursement Support for Digital Care Opens Market Access
  • Cloud-Native Clinical Software Adoption Moves From Strategy to Execution
  • Clinical Validation Requirements Extend Deployment Timelines for AI-Driven Tools

Segment Analysis

Diagnostic Software held 33.22% of the Clinical-grade Medical Software market size in 2025. Radiology and pathology workflows supported this position, as AI triage helped manage high imaging volumes and limited specialist capacity. Radiology represented 1,163 of 1,524 FDA-cleared AI algorithms by March 2026, reflecting a mature product environment for diagnostic applications. A Nature Biomedical Engineering article stated that diagnostic imaging errors caused 40,000-80,000 preventable deaths annually in the United States and more than USD 4 billion in malpractice costs.

Therapeutic Software is forecast to grow at a 20.93% CAGR through 2031. The category includes applications used in cardiovascular, respiratory, and metabolic disease management, with payer coverage for prescription digital therapeutics remaining important to expansion. Monitoring Software, Disease Management Software, Clinical Decision Support Software, Clinical Workflow and Communication Software, Telehealth and Virtual Care Software, and Medical Imaging and Visualization Software make up the remaining clinical function categories. The Clinical-grade Medical Software industry can benefit when reimbursement coverage and clinical evidence support adoption beyond pilot programs.

Cloud-Based Software held 56.23% of the Clinical-grade Medical Software market size in 2025. Its position reflected health systems’ shift toward hosted applications, enterprise imaging, and analytics services. Cloud tools supported shared access to information across hospitals and outpatient settings and allowed providers to expand capacity without relying only on local infrastructure. Cloud deployment remained subject to security, privacy, and clinical continuity requirements.

Hybrid Software is forecast to grow at a 22.86% CAGR through 2031. Health systems use hybrid designs to retain latency-sensitive, tightly integrated, or regulation-constrained workloads on site while placing analytics, AI inference, and secondary imaging use cases in public cloud environments. A 2026 review described hybrid models that combined private hospital clouds, community clouds, and government cloud layers to support interoperability while protecting sensitive clinical records. On-Premise Software remains relevant in jurisdictions with strict data residency rules and in facilities with limited replacement budgets.

Complete Report Scope:

  • By Clinical Function
    • Diagnostic Software
    • Monitoring Software
    • Therapeutic Software
    • Disease Management Software
    • Clinical Decision Support Software
    • Clinical Information and Documentation Software
    • Clinical Workflow and Communication Software
    • Telehealth and Virtual Care Software
    • Medical Imaging and Visualization Software
    • Others
  • By Deployment
    • Cloud-Based Software
    • On-Premise Software
    • Hybrid Software
  • By Component
    • Software
    • Services
  • By Therapeutics Area
    • Oncology
    • Cardiology
    • Neurology
    • Radiology
    • Respiratory Diseases
    • Metabolic Disorders
    • Infectious Diseases
    • Immunology
    • Women's Health
    • Other Therapeutic Areas
  • By End User
    • Hospitals and Health Systems
    • Ambulatory Surgical Centers
    • Diagnostic and Imaging Centers
    • Home Healthcare Providers
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held a 42.76% share of the clinical-grade medical software market in 2025, supported by broad enterprise EHR adoption, multiple FDA-cleared AI tools, and mature payer frameworks for digital care. Providers added clinical capabilities while strengthening infrastructure against cyber risk. Mexico added demand as private hospital groups invested in digital infrastructure, while Canada remained an active buyer as providers evaluated alternatives to established platform suppliers.

Europe maintained a compliance-focused environment shaped by MDR requirements and GDPR data sovereignty rules. InterSystems announced in May 2026 that IntelliCare became the first AI-native EHR to receive EU MDR Class IIa certification. Such certifications can become important requirements in regulated tenders. Germany, the United Kingdom, and Northern Europe remained active users of clinical AI tools, while the GCC emerged for AI-native EHR adoption, with Medcare becoming the first EMEA provider to deploy InterSystems IntelliCare.

Asia-Pacific is forecast to grow at a 19.56% CAGR through 2031, supported by national digitization programs, hospital IT modernization, and local vendor development across China, India, Japan, South Korea, and Australia. China’s hospital upgrade cycles created procurement opportunities for enterprise imaging software, while India’s domestic health IT development supported accessible deployment models. South Korea’s K-Digital initiative and Australia’s My Health Record expansion also supported demand. South America, led by Brazil and Argentina, remained an emerging area as public hospital digitization created scalable procurement opportunities.


List of Companies Covered in this Report:

  • Aidoc Medical Ltd.
  • Athenahealth
  • Elsevier B.V.
  • Epic Systems
  • GE HealthCare Technologies Inc.
  • HeartFlow, Inc.
  • Intersystems
  • IQVIA
  • Koninklijke Philips
  • Lunit
  • Mckesson
  • Medical Information Technology
  • Medtronic
  • Merative, Inc.
  • NextGen Healthcare
  • NVIDIA
  • Optum
  • Oracle
  • Qure.ai Technologies Private Limited
  • SAS Institute
  • Siemens Healthineers

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 AI-Enabled Clinical Workflow Automation
4.2.2 EHR, PACS and LIS Integration Demand
4.2.3 Regulatory and Reimbursement Support for Digital Care
4.2.4 Cloud-Native Clinical Software Adoption
4.2.5 Alert Personalization to Reduce Clinician Cognitive Load
4.2.6 Clinical Software Localization for Underserved Specialist Markets
4.3 Market Restraints
4.3.1 Cybersecurity, Privacy and Ransomware Exposure
4.3.2 Clinical Validation and Evidence Requirements
4.3.3 Alert Fatigue from Layered Algorithmic Prompts
4.3.4 Fragmented Clinical Ownership of Software Procurement
4.4 Value/Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers Analysis
4.7.2 Bargaining Power of Buyers Analysis
4.7.3 Threat of New Entrants Analysis
4.7.4 Threat of Substitutes Analysis
4.7.5 Competitive Rivalry Analysis
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Clinical Function
5.1.1 Diagnostic Software
5.1.2 Monitoring Software
5.1.3 Therapeutic Software
5.1.4 Disease Management Software
5.1.5 Clinical Decision Support Software
5.1.6 Clinical Information and Documentation Software
5.1.7 Clinical Workflow and Communication Software
5.1.8 Telehealth and Virtual Care Software
5.1.9 Medical Imaging and Visualization Software
5.1.10 Others
5.2 By Deployment
5.2.1 Cloud-Based Software
5.2.2 On-Premise Software
5.2.3 Hybrid Software
5.3 By Component
5.3.1 Software
5.3.2 Services
5.4 By Therapeutics Area
5.4.1 Oncology
5.4.2 Cardiology
5.4.3 Neurology
5.4.4 Radiology
5.4.5 Respiratory Diseases
5.4.6 Metabolic Disorders
5.4.7 Infectious Diseases
5.4.8 Immunology
5.4.9 Women's Health
5.4.10 Other Therapeutic Areas
5.5 By End User
5.5.1 Hospitals and Health Systems
5.5.2 Ambulatory Surgical Centers
5.5.3 Diagnostic and Imaging Centers
5.5.4 Home Healthcare Providers
5.5.5 Others
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Aidoc Medical Ltd.
6.3.2 athenahealth, Inc.
6.3.3 Elsevier B.V.
6.3.4 Epic Systems Corporation
6.3.5 GE HealthCare Technologies Inc.
6.3.6 HeartFlow, Inc.
6.3.7 InterSystems Corporation
6.3.8 IQVIA Holdings Inc.
6.3.9 Koninklijke Philips N.V.
6.3.10 Lunit Inc.
6.3.11 McKesson Corporation
6.3.12 Medical Information Technology, Inc.
6.3.13 Medtronic plc
6.3.14 Merative, Inc.
6.3.15 NextGen Healthcare, Inc.
6.3.16 NVIDIA Corporation
6.3.17 Optum, Inc.
6.3.18 Oracle Corporation
6.3.19 Qure.ai Technologies Private Limited
6.3.20 SAS Institute Inc.
6.3.21 Siemens Healthineers AG
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aidoc Medical Ltd.
  • athenahealth, Inc.
  • Elsevier B.V.
  • Epic Systems Corporation
  • GE HealthCare Technologies Inc.
  • HeartFlow, Inc.
  • InterSystems Corporation
  • IQVIA Holdings Inc.
  • Koninklijke Philips N.V.
  • Lunit Inc.
  • McKesson Corporation
  • Medical Information Technology, Inc.
  • Medtronic plc
  • Merative, Inc.
  • NextGen Healthcare, Inc.
  • NVIDIA Corporation
  • Optum, Inc.
  • Oracle Corporation
  • Qure.ai Technologies Private Limited
  • SAS Institute Inc.
  • Siemens Healthineers AG